|
Zhejiang Jolly Pharmaceutical Co., Ltd (300181.sz) Avaliação DCF
CN | Healthcare | Biotechnology | SHZ
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Zhejiang Jolly Pharmaceutical Co.,LTD (300181.SZ) Bundle
Simplifique sua análise e melhore a precisão com a calculadora DCF (300181SZ)! Equipado com dados atualizados da Zhejiang Jolly Pharmaceutical Co., LTD e suposições personalizáveis, essa ferramenta capacita você a prever, avaliar e avaliar o valor de (300181SZ) como um investidor experiente.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 911.2 | 1,090.9 | 1,457.4 | 1,805.2 | 1,942.5 | 2,354.3 | 2,853.3 | 3,458.2 | 4,191.2 | 5,079.7 |
| Revenue Growth, % | 0 | 19.72 | 33.6 | 23.86 | 7.61 | 21.2 | 21.2 | 21.2 | 21.2 | 21.2 |
| EBITDA | 103.0 | 184.0 | 294.2 | 393.0 | 522.9 | 456.9 | 553.8 | 671.2 | 813.5 | 985.9 |
| EBITDA, % | 11.3 | 16.87 | 20.19 | 21.77 | 26.92 | 19.41 | 19.41 | 19.41 | 19.41 | 19.41 |
| Depreciation | 50.6 | 56.4 | 59.6 | 63.9 | 68.5 | 103.0 | 124.9 | 151.3 | 183.4 | 222.3 |
| Depreciation, % | 5.56 | 5.17 | 4.09 | 3.54 | 3.53 | 4.38 | 4.38 | 4.38 | 4.38 | 4.38 |
| EBIT | 52.4 | 127.6 | 234.6 | 329.1 | 454.4 | 353.9 | 428.9 | 519.9 | 630.1 | 763.6 |
| EBIT, % | 5.75 | 11.7 | 16.09 | 18.23 | 23.39 | 15.03 | 15.03 | 15.03 | 15.03 | 15.03 |
| Total Cash | 138.7 | 314.8 | 297.8 | 1,092.9 | 1,083.0 | 851.4 | 1,031.8 | 1,250.5 | 1,515.6 | 1,836.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 310.7 | 308.2 | 337.3 | 510.1 | 532.4 | 664.7 | 805.6 | 976.3 | 1,183.3 | 1,434.1 |
| Account Receivables, % | 34.1 | 28.25 | 23.15 | 28.26 | 27.41 | 28.23 | 28.23 | 28.23 | 28.23 | 28.23 |
| Inventories | 201.3 | 201.4 | 273.6 | 318.8 | 426.5 | 465.9 | 564.7 | 684.3 | 829.4 | 1,005.2 |
| Inventories, % | 22.09 | 18.47 | 18.77 | 17.66 | 21.96 | 19.79 | 19.79 | 19.79 | 19.79 | 19.79 |
| Accounts Payable | 181.4 | 118.8 | 193.9 | 468.9 | 433.9 | 435.1 | 527.3 | 639.1 | 774.6 | 938.8 |
| Accounts Payable, % | 19.9 | 10.89 | 13.3 | 25.97 | 22.33 | 18.48 | 18.48 | 18.48 | 18.48 | 18.48 |
| Capital Expenditure | -40.5 | -58.4 | -148.0 | -178.0 | -131.7 | -172.3 | -208.8 | -253.0 | -306.7 | -371.7 |
| Capital Expenditure, % | -4.44 | -5.35 | -10.15 | -9.86 | -6.78 | -7.32 | -7.32 | -7.32 | -7.32 | -7.32 |
| Tax Rate, % | 14.26 | 14.26 | 14.26 | 14.26 | 14.26 | 14.26 | 14.26 | 14.26 | 14.26 | 14.26 |
| EBITAT | 45.9 | 103.8 | 189.3 | 277.2 | 389.6 | 297.1 | 360.1 | 436.4 | 528.9 | 641.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -274.5 | 41.6 | 74.7 | 220.1 | 161.3 | 57.5 | 128.7 | 156.0 | 189.1 | 229.2 |
| WACC, % | 5.28 | 5.28 | 5.28 | 5.28 | 5.28 | 5.28 | 5.28 | 5.28 | 5.28 | 5.28 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 635.6 | |||||||||
| Long Term Growth Rate, % | 3.50 | |||||||||
| Free cash flow (T + 1) | 237 | |||||||||
| Terminal Value | 13,322 | |||||||||
| Present Terminal Value | 10,299 | |||||||||
| Enterprise Value | 10,935 | |||||||||
| Net Debt | -710 | |||||||||
| Equity Value | 11,645 | |||||||||
| Diluted Shares Outstanding, MM | 696 | |||||||||
| Equity Value Per Share | 16.72 |
What You Will Receive
- Customizable Excel Template: A fully adaptable Excel-based DCF Calculator featuring pre-filled financial data for Zhejiang Jolly Pharmaceutical Co., LTD (300181SZ).
- Comprehensive Data: Access to historical financial information and forward-looking projections (highlighted in the yellow cells).
- Flexible Forecasting: Adjust key assumptions such as revenue growth, EBITDA percentage, and WACC easily.
- Instant Calculations: Observe how your inputs affect the valuation of Zhejiang Jolly Pharmaceutical Co., LTD (300181SZ) in real-time.
- Professional Resource: Designed for investors, CFOs, consultants, and financial analysts alike.
- Intuitive Interface: Organized for user clarity and convenience, complete with step-by-step guidance.
Key Features
- Customizable Forecast Inputs: Adjust essential parameters such as revenue growth, EBITDA %, and capital expenditures tailored to [Symbol] (300181SZ).
- Instant DCF Valuation: Automatically computes intrinsic value, net present value (NPV), and additional metrics for [Symbol] (300181SZ) in real-time.
- High Precision Analysis: Leverages Zhejiang Jolly Pharmaceutical's actual financial data for accurate valuation estimates.
- Effortless Scenario Testing: Easily evaluate various assumptions and analyze their impacts on outcomes for [Symbol] (300181SZ).
- Efficiency Booster: Streamlines the valuation process by removing the need to create intricate models from the ground up.
How It Operates
- Download the Template: Gain immediate access to the Excel-based ZJLY DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, profit margins, and more.
- Instant Calculations: The model automatically refreshes to show Zhejiang Jolly Pharmaceutical's intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
- Analyze and Decide: Utilize the outcomes to inform your investment or financial strategy.
Why Choose This Calculator for Zhejiang Jolly Pharmaceutical Co.,LTD (300181SZ)?
- Precise Financials: Real data from Jolly Pharmaceutical guarantees trustworthy valuation outcomes.
- Flexible Customization: Modify essential inputs like growth rates, WACC, and tax rates to align with your forecasts.
- Efficiency Boost: Built-in calculations save you time, eliminating the need to begin from the ground up.
- Professional-Quality Tool: Tailored for investors, analysts, and consultants focused on the pharmaceutical sector.
- Easy to Use: A user-friendly design and clear, step-by-step guidance make it accessible for everyone.
Who Can Benefit from This Product?
- Investors: Assess the valuation of Zhejiang Jolly Pharmaceutical (300181SZ) before making stock transactions.
- CFOs and Financial Analysts: Optimize valuation processes and evaluate financial projections.
- Startup Founders: Discover how prominent companies like Zhejiang Jolly Pharmaceutical (300181SZ) are valued.
- Consultants: Prepare detailed valuation reports for your clients.
- Students and Educators: Utilize real-time data to practice and teach valuation methodologies.
Contents of the Template
- Preloaded 300181SZ Data: Historical and projected financial information, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade templates for calculating intrinsic value and the Weighted Average Cost of Capital.
- Editable Inputs: Cells highlighted in yellow for modifying revenue growth, tax rates, and discount rates.
- Financial Statements: Detailed annual and quarterly financial statements for in-depth analysis.
- Key Ratios: Metrics for profitability, leverage, and efficiency to assess performance.
- Dashboard and Charts: Visual representations of valuation results and underlying assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.